The NASH Tsunami In Diabetes

Getting Ahead of the Rising Tide in Fatty Liver Disease

S2-E2 - A Deeper Dive Into Fatty Liver, NAFLD and NASH

S2-E2 – A Deeper Dive Into Fatty Liver, NAFLD, and NASH

In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.

Surfing The NASH Tsunami Podcast

Driving The Discussion In Fatty Liver Disease

Drug developers, investors, researchers, and corporate executives…

Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.

Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.

most recent episode ⤵

S4-12 - Deep Dive: ICER Draft Report on Resmetirom and Obeticholic Acid for NASH
SurfingNASH.Com is honored to have the following sponsors

S4-8.6 – Previewing Innovations in NAFLD Care 2022: Day Two Sessions

Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.

S4-8.5 – The Future of Digital Therapeutics

The podcast ventures into the emergence of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this final conversation, the panelists provide closing thoughts on the future of this space and how it may play out across different economic systems.

S4-8.4 – Digital Apps: Patient Participation and Regulatory Challenges

The podcast ventures into the emerging space of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. The panelists consider regulatory challenges for prescribing digital therapeutics as an evidence-based treatment. Additionally, Louise Campbell introduces a free lifestyle app that she is working on that aims to improve liver health.

S4-8.3 – Joe Rubinsztain on ChronWell and Scalable Technology

Joe Rubinsztain, CEO and Co-Founder of ChronWell, discusses scalable technology and the future of digital health. Within this context, the panelists consider the dynamics of insurers, providers and building an understanding around the full spectrum of disease treatment.

S4-8.1 – Utilizing Prescription Digital Therapeutics to Combat Fatty Liver

The podcast ventures into the emerging digital therapeutics space with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this conversation, both guests share their unique backgrounds and paths to combating Fatty Liver through technological innovation.

This is truly an excellent podcast…(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
This is truly an excellent podcast. Roger Green is joined by Akero Therapeutics' Kitty Yale, Manal Abdelmalek (Duke University), Naim Alkhouri (Arizona Liver Health) and Stephen Harrison from Pinnacle Clinical Research. They go through the FDA's recent webcast and dissect the meaning and directions laid out. Interesting points around histology remaining the surrogate for the evaluation of NASH and how we need to have a better way of quantifying NASH histology
FINALLY!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
A podcast for the NASH community! So many relevant topics. There are guest speakers almost every week who contribute a new energy to each episode. Keep up the good work coming!
I learn without trying(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
The host and other speakers are engaging to listen to yet not too serious or noting. I find mysweldf learning without trying. Excellent to have this on while working at home or driving while running errands.
At Long Last!(verified review) ⭐️⭐️⭐️⭐️⭐️
Read More
We have sorely needed a podcast that allows clinicians and academics to focus own major issues in NASH and NAFLD. Their recent coverage of ILC was timely and incisive. I find myself discussing the episodes with colleagues and Twitter buddies.
Previous
Next

Experience Nudge Learning! Interested in a new way of learning?